Last reviewed · How we verify
FluMist®
At a glance
| Generic name | FluMist® |
|---|---|
| Also known as | Live-attenuated influenza virus, LAIV, LAIV4, influenza virus vaccine LAIV4 |
| Sponsor | Stanford University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Exploratory Clinical Study of MT-2301 (PHASE2)
- Immune Defense Protein Impact On Respiratory Immune Outcomes (NA)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza (PHASE2)
- Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |